Navigation Links
UF scientists to work with German firm in prostate cancer treatment research
Date:6/18/2008

GAINESVILLE, Fla. University of Florida department of urology officials signed an agreement Tuesday to collaborate with the German biopharmaceutical company CureVac to test an experimental therapy for advanced prostate cancer patients who no longer respond to traditional treatment.

CureVac which specializes in the therapeutic application of messenger RNA, a biomolecule that transfers genetic information from nuclear DNA to cellular protein production machinery is developing a stabilized mRNA-derived vaccine for treatment of prostate cancer.

UF researchers will conduct a phase 1/2 clinical trial of the therapy in patients from the United States with metastatic prostate cancer who no longer respond to hormone therapy. Both institutions hope the initial collaboration will result in a better biologic product to work with in the second phase of the clinical trial.

"The agreement with the University of Florida represents our first step to the U.S. as the world's leading pharmaceutical marketplace with world-class academic institutions for research and development," said Thomas Lander, M.D., managing director and chief medical officer of CureVac.

In what will be the first direct-application trial of its kind in the United States, researchers plan to test molecules that have shown the potential to stimulate an immune response against tumors when injected into the skin, potentially providing an alternative therapy for this form of cancer.

"Several studies support the therapeutic potential of mRNA for the treatment of cancer," said Johannes Vieweg, M.D., a professor and chairman of UF's department of urology who is a member of CureVac's scientific advisory board. "This, however, will be the first clinical trial in the U.S. to use the direct application route by injecting modified mRNA into the skin."

UF urology researchers have treated more than 500 patients using RNA-based dendritic cells, which have been used in vaccines to treat the cancer, but these cells are difficult to manufacture and are often limited in quantity. Researchers hope to discover whether CureVac's technology may be an equivalent or more effective therapy to stimulate tumor response, Vieweg said.

"Our extensive experience and expertise in immunological monitoring and vaccine development are of value to companies such as CureVac, I believe, making us an attractive partner to work with," Vieweg said.

The Prostate Cancer Foundation estimates nearly 200,000 men will be diagnosed with prostate cancer in the United States in 2008. Treatment options generally include surgery or radiation if patients are diagnosed at an early stage. Hormone therapy is often used when cancer has spread beyond the prostate gland.

The proposed clinical trial is expected to begin in 2009. In the first phase of the trial, researchers will seek to define the optimal dose level of the therapy, as well as establish safety and evaluate improvements needed for the regimen. A European clinical trial is also planned.


'/>"/>

Contact: Melissa M. Thompson
thompsmelissa@gmail.com
352-273-5810
University of Florida
Source:Eurekalert

Related medicine news :

1. Scientists from Granada drastically reduce the wait time for new teeth implant
2. Possible link between different forms of epilepsy found by Carnegie Mellon scientists
3. Scientists Discover Protein Involved in Fat Production
4. Twenty of Americas Most Promising Scientists Selected as 2008 Pew Scholars in the Biomedical Sciences
5. QBI neuroscientists make Alzheimers disease advance
6. EPA scientists recognized with prestigious honor
7. 2collab Survey Reveals That Scientists and Researchers are "All Business" With Social Applications
8. Scientists ID Brain Pathway That Stops Seizures
9. Scientists ID Gene Regulating Blood Glucose Levels
10. South African scientists access European research via EMBC agreement
11. Zebrafish enable scientists to study the migration of neurons that enable sexual maturity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... ... semi-final round of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired by Under Armour ... in 2017. The entrepreneurs will showcase their businesses on February 6, 2017, at ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... today that its annual Solutions Series of webinars will start January 31 with ... discussing a number of current health and benefits topics, including employee engagement, pricing ...
(Date:1/24/2017)... ... January 24, 2017 , ... His message has been heard by more than ... End Distracted Driving , Joel Feldman, has reached his biggest national audience yet: the ... of the top newspapers in circulation in the country, and he hopes it will ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... Center ... 21st century leadership, has named Hector M. Chavez, Manager, Employee & Labor Relations at ... center - as its Hispanic Leader of the Month. City of Hope is committed ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... is the focus of a new report from the Frank Hawkins Kenan ... School. , Influential business leaders, academics and policy makers identified concrete solutions at ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Aptuit, LLC, hat heute den ... Massachusetts General Hospital (MGH) unter Leitung von Dr. ... Identifizierung und Validierung neuartiger Targets in gramnegativen Bakterien.  Aptuit ... von Antibiotika bei der Behandlung schwerer Infektionen entgegenwirken können. ... ...
(Date:1/24/2017)... -- Laboratory Markets Limited has completed a comprehensive market ... both clinical and research laboratory settings. This study, which ... $6.8 billion and growing to $9.2 billion (CAGR of ... of mass spectrometry across more than 5,200 clinical and ... in the use of mass spectrometry in terms of ...
(Date:1/24/2017)... 2017 Global Market for Pharmaceutical ... A majority of medicines & drugs produced in ... (API), and such processes require alcoholic solvents such as ... of pharmaceutical solvents continues to be concentrated in the ... (APEJ) region as leading API suppliers and ...
Breaking Medicine Technology: